Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Functional investigations of thromboxane synthase (CYP5A1) in lipid bilayers of nanodiscs.

Das A, Varma SS, Mularczyk C, Meling DD.

Chembiochem. 2014 Apr 14;15(6):892-9. doi: 10.1002/cbic.201300646. Epub 2014 Mar 12.

PMID:
24623680
2.

Functional role of the conserved i-helix residue I346 in CYP5A1-Nanodiscs.

Meling DD, Zelasko S, Kambalyal A, Roy J, Das A.

Biophys Chem. 2015 May-Jun;200-201:34-40. doi: 10.1016/j.bpc.2015.03.002. Epub 2015 Mar 12.

PMID:
25900452
4.

Resonance Raman investigation of the interaction of thromboxane synthase with substrate analogues.

Chen Z, Wang LH, Schelvis JP.

Biochemistry. 2003 Mar 11;42(9):2542-51.

PMID:
12614148
5.

Substrate binding is the rate-limiting step in thromboxane synthase catalysis.

Wang LH, Tsai AL, Hsu PY.

J Biol Chem. 2001 May 4;276(18):14737-43. Epub 2001 Jan 31.

6.

Protein engineering of thromboxane synthase: conversion of membrane-bound to soluble form.

Hsu PY, Wang LH.

Arch Biochem Biophys. 2003 Aug 1;416(1):38-46.

PMID:
12859980
8.
9.

Effect of specific phospholipid molecular species incorporated in human platelet membranes on thromboxane A2/prostaglandin H2 receptors.

Bayon Y, Croset M, Daveloose D, Guerbette F, Chirouze V, Viret J, Kader JC, Lagarde M.

J Lipid Res. 1995 Jan;36(1):47-56.

10.

Identification of genetic variants in the human thromboxane synthase gene (CYP5A1).

Chevalier D, Lo-Guidice JM, Sergent E, Allorge D, Debuysère H, Ferrari N, Libersa C, Lhermitte M, Broly F.

Mutat Res. 2001 Jan;432(3-4):61-7.

PMID:
11465543
11.

Purification and characterization of recombinant human prostacyclin synthase.

Wada M, Yokoyama C, Hatae T, Shimonishi M, Nakamura M, Imai Y, Ullrich V, Tanabe T.

J Biochem. 2004 Apr;135(4):455-63.

12.

Liver microsomal lipid enhances the activity and redox coupling of colocalized cytochrome P450 reductase-cytochrome P450 3A4 in nanodiscs.

Liu KC, Hughes JMX, Hay S, Scrutton NS.

FEBS J. 2017 Jul;284(14):2302-2319. doi: 10.1111/febs.14129. Epub 2017 Jun 30.

13.

Thromboxane synthase catalyses hydroxylations of prostaglandin H2 analogs in the presence of iodosylbenzene.

Hecker M, Baader WJ, Weber P, Ullrich V.

Eur J Biochem. 1987 Dec 15;169(3):563-9.

14.
15.

Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes.

Nath A, Grinkova YV, Sligar SG, Atkins WM.

J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15.

17.

Enrichment of platelet phospholipids with eicosapentaenoic acid and docosahexaenoic acid inhibits thromboxane A2/prostaglandin H2 receptor binding and function.

Swann PG, Parent CA, Croset M, Fonlupt P, Lagarde M, Venton DL, Le Breton GC.

J Biol Chem. 1990 Dec 15;265(35):21692-7.

18.
19.

Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.

Dorn GW 2nd, Burch RM, Kochel PJ, Mais DE, Halushka PV.

Biochem Pharmacol. 1987 Jun 15;36(12):1913-7.

PMID:
2954555
20.

Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.

Golino P, Ambrosio G, Villari B, Ragni M, Focaccio A, Pace L, de Clerk F, Condorelli M, Chiariello M.

J Am Coll Cardiol. 1993 Feb;21(2):493-501.

Supplemental Content

Support Center